Shiga toxin 2 and lipopolysaccharide cause monocytic THP-I cells to release factors which activate platelet function

Thrombosis and Haemostasis

Volumn 94, Issue 5, 2005, Pages 1019-1027

  Guessous, Fadila ^a   Marcinkiewicz, Marek ^a   Polanowska Grabowska, Renata ^a   Keepers, Tiffany R ^a   Obrig, Tom ^a   Gear, Adrian R L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Aggregation; Chemokines; Hemolytic uremic syndrome (HUS); IL 8; Lipopolysaccharide (LPS); Monocytes (THP I); Platelets; RANTES; Secretion; Shiga toxin

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CHEMOKINE; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; PADGEM PROTEIN; RANTES; SEROTONIN; VEROTOXIN 2;

ARTICLE; CELL INTERACTION; CONTROLLED STUDY; ESCHERICHIA COLI O157; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; KIDNEY FAILURE; MONOCYTE; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

BLOOD PLATELETS; CELL COMMUNICATION; CELL LINE, TUMOR; CHEMOKINES, CC; CYTOPLASMIC GRANULES; HUMANS; INTERLEUKIN-8; LEUKEMIA; LIPOPOLYSACCHARIDES; MONOCYTES; PLATELET AGGREGATION; RANTES; SHIGA-LIKE TOXIN II;

EID: 27844538829     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-02-0115     Document Type: Article

References (47)

1. Gasser C, Gautieer E, Steck A et al. Hämolytischuramische Syndrome: Bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytishen Anämien. Schweiz Med Wochenschr 1955; 85: 905-909.
2. Huppertz H, Busch D, Schmidt H et al. Diarrhea in young children associated with Escherichia coli non-O157 organisms that produce Shiga-like toxin. J Pediatr 1996; 128: 341-6.
3. Ludwig K, Sarkim V, Bitzan M et al. Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol 2002; 40: 1773-82.
4. Blackall DP, Marques MB. Hemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generation. Am J Clin Pathol 2004; 121 Suppl: S81-88.
5. Appiani AC, Edefonti A, Bettinelli A. The relationship between plasma levels of the factor VIII complex and platelet release products β-thromboglobulin and platelet factor 4) in children with the hemolytic-uremic syndrome. Clin Nephrol 1982; 17: 195-9.
6. Walters MD, Levin M, Smith C et al. Intravascular platelet activation in the hemolytic uremic syndrome. Kidney Int 1988; 33: 107-15.
7. Yoshimura K, Fujii Yutsudo T et al. No direct effects of Shiga toxin 1 and 2 on the aggregation of human platelets in vitro. Thromb Haemost 1998; 80: 529-30.
8. Thorpe CM, Flaumenhaft R, Hurley B et al. Shiga toxins do not directly stimulate alpha-granule secretion or enhance aggregation of human platelets. Acta Haematol 1999; 102: 51-5.
9. Viisoreanu D, Polanowska-Grabowska R, Suttitanamongkol S et al Human platelet aggregation is not altered by Shiga toxins 1 or 2. Thromb Res 2000; 98: 403-10.
10. Koster F, Levin J, Walker L et al. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N Engl J Med 1978; 298: 927-33.
11. Bitzan M, Moebius E, Ludwig K et al. High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic uremic syndrome. J Pediatr 1991; 119: 380-5.
12. Karpman D, Connell H, Svensson M et al. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis 1997; 175: 611-20.
13. van Setten PA, Monnens LA, Verstraten RG et al. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 1996; 88: 174-83.
14. Harrison LM, van Haaften WCE, Tesh VL. Regulation of proinflammatory cytokine expression by Shiga toxin 1 and/or lipopolysaccharides in the human monocytic cell line THP-1. Infect Immun 2004; 72: 2618-27.
15. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10: 335-50.
16. Shenkman B, Brill A, Brill G et al. Differential response of platelets to chemokines: RANTES non-competitively inhibits stimulatory effect of SDF-1alpha. J Thromb Haemost 2004; 2: 154-60.
17. Suttitanamongkol S, Gear AR. ADP receptor antagonists inhibit platelet aggregation induced by the chemokines SDF-1, MDC and TARC. FEBS Lett 2001; 490: 84-7.
18. Gear AR. Rapid reactions of platelets studied by a quenched-flow approach: aggregation kinetics. J Lab Clin Med 1982; 100: 866-86.
19. Goldsmith HL, Turitto VT. Rheological aspects of thrombosis and haemostasis: basic principles and applications. ICTH-Report - Subcommittee on Rheology of the International Committee on Thrombosis and Haemostasis. Thromb Haemost 1986; 55: 415-35.
20. Jones GD, Carty DJ, Freas DL et al. Effects of separate proteolytic and high-affinity binding activities of human thrombin on rapid platelet activation. A quenched-flow study. Biochem J 1989; 262: 611-6.
21. Karmali MA, Petric M, Lim C et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151: 775-82.
22. Taylor FB, Tesh VL, DeBault L et al. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 1999; 154: 1285-99.
23. Ghosh SA, Polanowska-Grabowska R, Fujii J et al. Shiga toxin binds to activated platelets. J Thromb Haemost 2004; 2: 499-506.
24. Brueckmann M, Hoffmann U, De Rossi L et al. Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes. Cytokine 2004; 26: 106-13.
25. Sakamoto H, Aikawa M, Hill CC et al. Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension. Circulation 2001; 104: 109-14.
26. Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 2001; 86: 214-21.
27. Karpman D, Papadopoulou D, Nilsson K et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 2001; 97: 3100-8.
28. Baltus T, von Hundelshausen P, Mause SF et al. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol 2005; 78: 435-41.
29. Eriksson EE. Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects. Curr Opin Lipidol 2004; 15: 553-8.
30. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
31. Leytin V, Shakoor S, Mody M. Sepsis- and endotoxemia-generated cytokines do not trigger activation of human platelets. Crit Care Med 2002; 30: 27713.
32. Gear AR, Suttitanamongkol S, Viisoreanu D,et al. Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function. Blood 2001; 97: 937-45.
33. Marcus AJ, Brockman MJ, Drosopoulos JH et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997; 99: 1351-60.
34. Robson SC, Kaczmarek E, Siegel JB et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 1997; 185: 153-63.
35. Steen VM, Holmsen H, Aarbakke G. The platelet-stimulating effect of adrenaline through alpha 2-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Evidence that adrenaline per se does not induce human platelet activation in vitro. Thromb Haemost 1993; 70: 506-13.
36. Clemetson KJ, Clemetson JM, Proudfoot AE et al. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 2000; 96: 4046-54.
37. Huo Y, Schober A, Forlow SB et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-7.
38. Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 2002; 105: 2130-2.
39. Gawaz M, Dickfeld T, Bogner C et al. Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med 1997; 23: 379-85.
40. Nieuwland R, Berckmans RJ, McGregor S et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95: 930-5.
41. Ogura H, Kawasaki T, Tanaka H et al. Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma 2001; 50: 801-9.
42. Brass, L, Molino M. Protease-activated G protein-coupled receptors on human platelets and endothelial cells. Thromb Haemost 1997; 78: 234-41.
43. Schmid DI, Kohan DE. Effect of shigatoxin-1 on arachidonic acid release by human glomerular epithelial cells. Kidney Int 2001; 60: 1026-36.
44. Tonshoff B, Momper R, Kuhl PG et al. Increased thromboxane biosynthesis in childhood hemolytic uremic syndrome. Kidney Int 1990; 37: 1134-41.
45. Noris M, Benigni A, Siegler R et al. Renal prostacyclin biosynthesis is reduced in children with hemolytic-uremic syndrome in the context of systemic platelet activation. Am J Kidney Dis 1992; 20: 144-9.
46. Harrison LM, van den Hoogen C, van Haaften WC et al. Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides. Infect Immun 2005; 73: 403-12.
47. Montrucchio G, Bosco O, Del Sorbo L et al. Mechanisms of the priming effect of low doses of lipopolysaccharides on leukocyte-dependent platelet aggregation in whole blood. Thromb Haemost 2003; 90: 872-81.